Acquisition delivers simplicity and access, supporting physicians across the full procedural workflow

采集功能带来简洁性与便捷性，支持医师贯穿整个手术工作流程

GALWAY, Ireland

爱尔兰，戈尔韦

,

，

June 12, 2026

2026年6月12日

/

/

PRNewswire

美通社

/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of Scientia Vascular, a privately-held medical device company in Salt Lake City. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition..

/ -- 全球医疗技术领导者美敦力公司（纽约证券交易所代码：MDT）今日宣布，已完成对位于盐湖城的私营医疗器械公司Scientia Vascular的收购。该收购交易价值为5.5亿美元，需按惯例进行调整，并可能在收购后支付未披露的盈利对价和里程碑付款。

Scientia has developed best-in-class access products that enable simplicity and access for physicians treating complex neurovascular conditions. Scientia's portfolio of guidewires and catheters can be seamlessly integrated with Medtronic's existing suite of neurovascular products, strengthening the company's ability to support physicians across the full procedural workflow..

Scientia 开发了行业领先的通路产品，为治疗复杂神经血管疾病的医生提供简便性和通路支持。Scientia 的导丝和导管产品组合可与美敦力现有的神经血管产品系列无缝整合，从而增强公司为医生在整个手术流程中提供支持的能力。

'Since its founding, Scientia has been driven by a commitment to improving patients' lives and supporting the physicians who care for them,' said Rick Randall, CEO of Scientia. 'Joining Medtronic is an exciting next step for our team, as their Mission closely aligns with the values that have guided Scientia from the beginning.

“自成立之初，Scientia始终秉持改善患者生活、支持照护患者的医师的承诺。”Scientia首席执行官Rick Randall表示，“加入美敦利是我们团队令人振奋的下一步，因为他们的使命与指引Scientia自始以来的价值观高度契合。”

With Medtronic's global scale, we look forward to bringing this technology to more physicians and reaching more patients around the world.'.

凭借美敦力的全球规模，我们期待将这项技术带给更多的医生，惠及全球更多的患者。

'The addition of Scientia's access technologies strengthens our ability to simplify complex neurovascular procedures and support physicians with more seamless solutions,' said Linnea Burman, senior vice president and president of Medtronic's Neurovascular business, part of the Neuroscience Portfolio at Medtronic.

“加入Scientia的介入技术，增强了我们简化复杂神经血管手术、并为医生提供更无缝解决方案的能力。”美敦力神经科学产品组合旗下神经血管业务高级副总裁兼总裁Linnea Burman表示。

'By bringing together highly complementary technologies, we are building a more integrated platform that will help advance the future of neurovascular care and enable physicians to treat more patients with greater efficiency and confidence.'.

“通过整合高度互补的技术，我们正在构建一个更加一体化的平台，这将有助于推动神经血管护理的未来发展，并使医生能够以更高效、更自信的方式治疗更多患者。”

In stroke treatment, every second matters. With each second of restricted blood flow, the brain loses millions of brain cells. Today, stroke is the third leading cause of death and leading cause of disability worldwide.

在卒中治疗中，每一秒都至关重要。每过一秒钟血流受阻，大脑就会损失数百万个脑细胞。目前，卒中是全球第三大致死原因，也是致残的首要原因。

Unlike vessels in many other parts of the body, cerebral vasculature is highly complex and tortuous, creating significant challenges for physicians attempting to reach the site of an occlusion or aneurysm. Difficult access can delay therapy delivery and impact procedural success.

与身体其他许多部位的血管不同，脑血管系统高度复杂且迂曲，给试图到达闭塞或动脉瘤部位的医生带来了重大挑战。通路困难可能延迟治疗实施，并影响手术成功率。

Scientia's novel access platform is designed to address these challenges by improving navigability through complex anatomy and simplifying neurovascular procedures. By enabling faster and more reliable access, these technologies improve procedural efficiency.

Scientia 的新型介入平台旨在通过改善在复杂解剖结构中的导航能力并简化神经血管手术，来应对这些挑战。这些技术通过实现更快速、更可靠的介入通路，提高了手术效率。

This acquisition reflects Medtronic's continued focus on strategic deals that strengthen its leadership across core businesses. The company remains committed to pursuing high-growth opportunities that complement its portfolio and enhance value for physicians and hospital partners.

此次收购体现了美敦力持续专注于通过战略性交易巩固其在核心业务领域的领导地位。公司仍致力于寻求高增长机会，以补充其产品组合，并为医生及医院合作伙伴提升价值。

Financial Impact

财务影响

This acquisition is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter.

预计此次收购在2027财年将使美敦力调整后的每股收益受到轻微稀释，此后将产生增厚效应。

About Scientia Vascular

关于 Scientia Vascular

Scientia is a private company operating in Salt Lake City, with approximately 310 employees. Under founder and chief technology officer John Lippert, the company has developed best-in-class access products that enable simplicity and access for physicians treating complex neurovascular conditions. Scientia's portfolio of guidewires and catheters can be seamlessly integrated with Medtronic's existing suite of neurovascular products, strengthening the company's ability to support physicians across the full procedural workflow..

Scientia 是一家总部位于盐湖城的私营公司，拥有约310名员工。在创始人兼首席技术官 John Lippert 的带领下，公司开发了行业领先的通路产品，为治疗复杂神经血管疾病的医生提供简便高效的通路解决方案。Scientia 的导丝和导管产品组合可与美敦力现有的神经血管产品系列无缝整合，从而增强公司为医生在整个手术流程中提供支持的能力。

About the Neurovascular Business at Medtronic

关于美敦力神经血管业务

Medtronic helped create the neurovascular market – introducing innovations like liquid embolic, stent retrievers, and flow diverters. Today, with products covering multiple conditions and disease states, we work to eliminate the burden of stroke and other neurovascular diseases globally by transforming care, one breakthrough at a time.

美敦力助力开创了神经血管市场，推出了液体栓塞剂、取栓支架和血流导向装置等创新产品。如今，凭借涵盖多种病症和疾病状态的产品组合，我们致力于通过一次次突破变革诊疗模式，从而消除全球范围内卒中及其他神经血管疾病带来的负担。

Together with our partners, including physicians, hospitals, governments and patients, we're expanding into new disease states and stages of care. Our unwavering focus on better outcomes fuels our drive to deliver life-changing therapies and transform the future of care for patients worldwide. For more information, follow Medtronic Neurovascular on .

我们与包括医生、医院、政府和患者在内的合作伙伴携手，不断拓展新的疾病领域和护理阶段。我们坚定不移地致力于改善治疗效果，这推动着我们提供改变生命的疗法，并重塑全球患者未来的护理模式。欲了解更多信息，请关注 Medtronic Neurovascular 的 。

LinkedIn

领英

.

。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考，更大胆行动。我们是美敦力。美敦力公司（Medtronic plc）总部位于爱尔兰戈尔韦，是全球领先的医疗科技公司，通过积极探索并寻找解决方案，勇敢应对人类面临的最严峻健康挑战。我们的使命——减轻病痛、恢复健康、延长寿命——凝聚了遍布150多个国家的95,000多名充满热情的员工。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法涵盖70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监护系统等。凭借我们多元的知识储备、永不满足的好奇心以及帮助所有需要帮助之人的愿望，我们提供创新技术，每秒钟、每小时、每天都在改变着两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

随着我们赋能洞察驱动的医疗护理、打造以人为本的体验，并为我们的世界带来更佳的成果，您将看到我们更多的作为。在我们的每一项工作中，我们都在匠心铸就非凡。欲了解更多关于美敦力的信息，请访问。

www.Medtronic.com

www.Medtronic.com

and follow Medtronic on

并关注美敦力

LinkedIn

领英

.

。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述均受限于风险和不确定性，例如美敦力公司向美国证券交易委员会提交的定期报告中所描述的那些。实际结果可能与预期结果存在重大差异。

Contacts:

联系人：

Justin Paquette

贾斯汀·帕凯特

Ingrid Goldberg

英格丽德·戈德堡

Public Relations

公共关系

Investor Relations

投资者关系

+1-612-271-7935

+1-612-271-7935

+1-612-505-2696

+1-612-505-2696

SOURCE Medtronic plc

来源：美敦力公司